{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T02:17:13Z","timestamp":1784945833481,"version":"3.55.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Geriatr"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The concurrent use of anticholinergics and acetylcholinesterase inhibitors (ACHEIs) in Parkinson\u2019s disease (PD) patients with dementia should be avoided because the opposing pharmacological actions of both drugs reduce the treatment efficacy. We aimed to investigate the prevalence of the concurrent use of these two types of drugs in Korean patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In the 2017 Health Insurance Review and Assessment Service\u2013National Aged Patient Sample data, comprising insurance claims records for a 10% random sample of patients aged\u2009\u2265\u200965\u00a0years in Korea, \u201cconcurrent use\u201d was defined as the overlapping of anticholinergic and ACHEI doses for at least 2\u00a0months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 8,845 PD patients with dementia, 847 (9.58%) were co-administered anticholinergics, used to treat the motor symptoms of PD, and ACHEIs for a mean duration of 7.7\u00a0months. A total of 286 (33.77% of all co-administered) patients used both drug types concurrently all year. About 80% of concurrent users were prescribed each drug by the same prescriber, indicating that coadministration may not be due to a lack of information sharing between providers. Logistic regression analysis showed that patients mainly treated at clinics (odds ratio (OR), 1.541; 95% confidence interval (CI), 1.158\u20132.059), hospitals (OR, 2.135; 95% CI, 1.586\u20132.883), and general hospitals (OR, 1.568; 95% CI, 1.221\u20132.028) were more likely to be co-prescribed anticholinergics and ACHEIs than those mainly treated at tertiary-care hospitals. PD patients with dementia treated at healthcare organizations located in areas other than the capital city had an approximately 22% higher risk of concurrent use (OR: 1.227, 95% CI: 1.046\u20131.441).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The concurrent use of anticholinergics for the motor symptoms of PD and ACHEIs in elderly Korean PD patients with dementia cannot be ignored, and strategies that mitigate potentially inappropriate concurrent drug use are required.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12877-022-03296-w","type":"journal-article","created":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T17:03:05Z","timestamp":1658422985000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prevalence and patterns of the concurrent use of anticholinergics for the motor symptoms of Parkinson\u2019s disease and acetylcholinesterase inhibitors in Parkinson\u2019s disease patients with dementia: a cross-sectional study using Korea National Health Insurance claims data"],"prefix":"10.1186","volume":"22","author":[{"given":"Deborah","family":"Baik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Mi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun-Young","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye-Young","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,21]]},"reference":[{"issue":"12","key":"3296_CR1","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/S1474-4422(10)70212-X","volume":"9","author":"AA Kehagia","year":"2010","unstructured":"Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson\u2019s disease. Lancet Neurol. 2010;9(12):1200\u201313.","journal-title":"Lancet Neurol"},{"issue":"4","key":"3296_CR2","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.ncl.2016.06.012","volume":"34","author":"A Lee","year":"2016","unstructured":"Lee A, Gilbert RM. Epidemiology of Parkinson Disease. Neurol Clin. 2016;34(4):955\u201365.","journal-title":"Neurol Clin"},{"key":"3296_CR3","unstructured":"Purves D, Augustine GJ, Fitzpatrick D, Hall WC, Lamantia A-S, Mcnamara JO, et al. Neuroscience: Sinauer Associates, Inc.; 2004."},{"issue":"1","key":"3296_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1001\/jamaneurol.2018.2820","volume":"76","author":"S Mantri","year":"2019","unstructured":"Mantri S, Fullard M, Gray SL, Weintraub D, Hubbard RA, Hennessy S, et al. Patterns of dementia treatment and frank prescribing errors in older adults with Parkinson Disease. JAMA Neurol. 2019;76(1):41\u20139.","journal-title":"JAMA Neurol"},{"key":"3296_CR5","unstructured":"Health Insurance Review and Assessment Service. Healthcare bigdata system. https:\/\/opendata.hira.or.kr\/home.do. Accessed 10 Jan 2019."},{"issue":"2","key":"3296_CR6","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/ggi.12457","volume":"16","author":"YS Oh","year":"2016","unstructured":"Oh YS, Kim JS, Park IS, Shim YS, Song IU, Park JW, et al. Prevalence and treatment pattern of Parkinson\u2019s disease dementia in Korea. Geriatr Gerontol Int. 2016;16(2):230\u20136.","journal-title":"Geriatr Gerontol Int"},{"issue":"16","key":"3296_CR7","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1001\/jama.2014.3654","volume":"311","author":"BS Connolly","year":"2014","unstructured":"Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311(16):1670\u201383.","journal-title":"JAMA"},{"key":"3296_CR8","doi-asserted-by":"publisher","first-page":"j1951","DOI":"10.1136\/bmj.j1951","volume":"358","author":"G Rogers","year":"2017","unstructured":"Rogers G, Davies D, Pink J, Cooper P. Parkinson\u2019s disease: summary of updated NICE guidance. BMJ. 2017;358:j1951 (Erratum in: BMJ. 2019;364:l961).","journal-title":"BMJ"},{"key":"3296_CR9","unstructured":"National Institute for Health and Care Excellence. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer\u2019s disease. https:\/\/www.nice.org.uk\/guidance\/ta217. Accessed 09 Oct 2019."},{"key":"3296_CR10","doi-asserted-by":"publisher","unstructured":"Nawaz H, Sargent L, Quilon H, et al. Anticholinergic medication burden in Parkinson\u2019s Disease outpatients [published online ahead of print, 2021 Nov 15]. J Parkinsons Dis. 2021;https:\/\/doi.org\/10.3233\/JPD-212769.\u00a0","DOI":"10.3233\/JPD-212769"},{"issue":"9","key":"3296_CR11","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.nrl.2012.05.004","volume":"29","author":"A Robles Bay\u00f3n","year":"2014","unstructured":"Robles Bay\u00f3n A, Gude SF. Inappropriate treatments for patients with cognitive decline. Neurologia. 2014;29(9):523\u201332. https:\/\/doi.org\/10.1016\/j.nrl.2012.05.004.","journal-title":"Neurologia"},{"key":"3296_CR12","doi-asserted-by":"publisher","first-page":"e2014008","DOI":"10.4178\/epih\/e2014008","volume":"36","author":"L Kim","year":"2014","unstructured":"Kim L, Kim JA, Kim S. A guide for the utilization of Health Insurance Review and Assessment Service National Patient Samples. Epidemiol Health. 2014;36:e2014008. https:\/\/doi.org\/10.4178\/epih\/e2014008 (Published 2014 Jul 30).","journal-title":"Epidemiol Health"},{"key":"3296_CR13","doi-asserted-by":"crossref","unstructured":"Parkinson\u2019s disease: summary of updated NICE guidance. BMJ. 2019;364:l961. Erratum for: Rogers G, Davies D, Pink J, Cooper P. Parkinson\u2019s disease: summary of updated NICE guidance. BMJ. 2017;358:j1951.","DOI":"10.1136\/bmj.j1951"},{"key":"3296_CR14","unstructured":"Artane (Trihexyphenidyl hydrochloride) Label. \u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2003\/006773_S036_ARTANE.pdf. Accessed 19 Jan\u00a02022."},{"key":"3296_CR15","unstructured":"Cogentin (benztropine mesylate) injection label.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/012015s026lbl.pdf. Accessed 19 Jan\u00a02022."},{"key":"3296_CR16","unstructured":"ARICEPT (donepezil hydrochloride) Label.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020690s035,021720s008,022568s005lbl.pdf. Accessed\u00a019 Jan\u00a02022."},{"key":"3296_CR17","unstructured":"Aricept Tablets - Summary of Product Characteristics (SmPC) - (emc).\u00a0https:\/\/www.medicines.org.uk\/emc\/product\/3776\/smpc#gref. Accessed\u00a019 Jan\u00a02022."},{"key":"3296_CR18","unstructured":"RAZADYNE (galantamine hydrobromide).\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021169Orig1s032,021224Orig1s030,021615Orig1s023lbl.pdf. Accessed 19 Jan\u00a02022."},{"key":"3296_CR19","unstructured":"Galantamine 4 mg\/ ml Oral Solution - Summary of Product Characteristics (SmPC) - (emc).\u00a0https:\/\/www.medicines.org.uk\/emc\/product\/6134\/smpc#gref. Accessed\u00a019 Jan\u00a02022."},{"key":"3296_CR20","unstructured":"Exelon Patch (rivastigimine) Label.\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/022083lbl.pdf. Accessed 19 Jan\u00a02022."},{"key":"3296_CR21","unstructured":"Exelon Capsules - Summary of Product Characteristics (SmPC) - (emc). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/exelon-epar-product-information_en.pdf. Accessed 19 Jan\u00a02022.\u00a0"},{"issue":"4","key":"3296_CR22","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/jgs.15767","volume":"67","author":"the 2019 American Geriatrics Society Beers Criteria\u00ae Update Expert Panel","year":"2019","unstructured":"the 2019 American Geriatrics Society Beers Criteria\u00ae Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674\u201394.","journal-title":"J Am Geriatr Soc"},{"key":"3296_CR23","doi-asserted-by":"publisher","first-page":"656370","DOI":"10.1155\/2014\/656370","volume":"2014","author":"N Divac","year":"2014","unstructured":"Divac N, Prostran M, Jakovcevski I, Cerovac N. Second-generation antipsychotics and extrapyramidal adverse effects. Biomed Res Int. 2014;2014:656370.","journal-title":"Biomed Res Int"},{"issue":"Suppl 1","key":"3296_CR24","doi-asserted-by":"publisher","first-page":"S108","DOI":"10.1016\/S1353-8020(13)70027-0","volume":"20","author":"PR Burkhard","year":"2014","unstructured":"Burkhard PR. Acute and subacute drug-induced movement disorders. Parkinsonism Relat Disord. 2014;20(Suppl 1):S108\u201312.","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"3296_CR25","first-page":"643","volume":"77","author":"BA Selius","year":"2008","unstructured":"Selius BA, Subedi R. Urinary retention in adults: diagnosis and initial management. Am Fam Physician. 2008;77(5):643\u201350.","journal-title":"Am Fam Physician"},{"issue":"5","key":"3296_CR26","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.bbadis.2016.01.015","volume":"1862","author":"RN Kalaria","year":"2016","unstructured":"Kalaria RN, Akinyemi R, Ihara M. Stroke injury, cognitive impairment and vascular dementia. Biochim Biophys Acta. 2016;1862(5):915\u201325.","journal-title":"Biochim Biophys Acta"}],"container-title":["BMC Geriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-022-03296-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12877-022-03296-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12877-022-03296-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T17:06:35Z","timestamp":1658423195000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgeriatr.biomedcentral.com\/articles\/10.1186\/s12877-022-03296-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,21]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3296"],"URL":"https:\/\/doi.org\/10.1186\/s12877-022-03296-w","relation":{},"ISSN":["1471-2318"],"issn-type":[{"value":"1471-2318","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,21]]},"assertion":[{"value":"16 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research protocol was approved by the Institutional Review Board (IRB) of Yonsei University, Seoul, South Korea (IRB No. 7001988-201910-HR-735-01E). The need for informed consent to participate from the study population was waived by Institutional Review Board (IRB) of Yonsei University, Seoul, South Korea on account of the retrospective nature of the study. All methods were performed in accordance with the declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there is no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"609"}}